In 2013, our group reported potent activity of silibinin in a NSCLC preclinical model of acquired resistance to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib [19–21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.